Details for Patent: 8,481,598

Which drugs does patent 8,481,598 protect, and when does it expire?

Patent 8,481,598 protects FETZIMA and is included in one NDA.

This patent has eight patent family members in four countries.

Summary for Patent: 8,481,598

Scope and claims summary:

Title:	Stable dosage forms of levomilnacipran
Abstract:	The present invention relates to stable dosage forms of levomilnacipran and pharmaceutically acceptable salts thereof. Processes for the preparation of these dosage forms and methods of using these dosage forms are also described.
Inventor(s):	Surana; Rahul (Commack, NY), Divi; Murali (Ronkonkoma, NY), Chhettry; Anil (Holtsville, NY)
Assignee:
Application Number:	13/006,993
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 8,481,598
Patent Claim Types: see list of patent claims	Use; Dosage form;

Drugs Protected by US Patent 8,481,598

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Abbvie	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-001	Jul 25, 2013		RX	Yes	No						TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Abbvie	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-002	Jul 25, 2013		RX	Yes	No						TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Abbvie	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-003	Jul 25, 2013		RX	Yes	No						TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
Abbvie	FETZIMA	levomilnacipran hydrochloride	CAPSULE, EXTENDED RELEASE;ORAL	204168-004	Jul 25, 2013		RX	Yes	Yes						TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

International Family Members for US Patent 8,481,598

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Canada	2779711
Canada	2790933
European Patent Office	2496079
European Patent Office	2536688
Japan	2013510176
Japan	2013517290